OCUL Quote, Financials, Valuation and Earnings

Editas Medicine has a net margin of -283.27% compared to Ocular Therapeutix's net margin of -148.33%. Ocular Therapeutix's return on equity of -62.66% beat Editas Medicine's return on equity of -100%.

Ocular Therapeutix has a consensus price target of $17.50, signalling upside risk potential of 126.98%. On the other hand Editas Medicine has an analysts' consensus of $3.75 which suggests that it could grow by 143.51%. Given that Editas Medicine has higher upside potential than Ocular Therapeutix, analysts believe Editas Medicine is more attractive than Ocular Therapeutix.

Ocular Therapeutix has a beta of 1.491, which suggesting that the stock is 49.133% more volatile than S&P 500. In comparison Editas Medicine has a beta of 2.165, suggesting its more volatile than the S&P 500 by 116.479%.

Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Editas Medicine offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. Editas Medicine pays out -- of its earnings as a dividend.

Ocular Therapeutix quarterly revenues are $17.1M, which are smaller than Editas Medicine quarterly revenues of $30.6M. Ocular Therapeutix's net income of -$48.4M is lower than Editas Medicine's net income of -$45.4M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while Editas Medicine's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 19.15x versus 3.92x for Editas Medicine. Usually stocks with elevated PS ratios are considered overvalued.

Ocugen has a net margin of -283.27% compared to Ocular Therapeutix's net margin of -1816.75%. Ocular Therapeutix's return on equity of -62.66% beat Ocugen's return on equity of -171.04%.

Ocular Therapeutix has a consensus price target of $17.50, signalling upside risk potential of 126.98%. On the other hand Ocugen has an analysts' consensus of $6.75 which suggests that it could grow by 838.54%. Given that Ocugen has higher upside potential than Ocular Therapeutix, analysts believe Ocugen is more attractive than Ocular Therapeutix.

Ocular Therapeutix has a beta of 1.491, which suggesting that the stock is 49.133% more volatile than S&P 500. In comparison Ocugen has a beta of 3.784, suggesting its more volatile than the S&P 500 by 278.402%.

Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.

Ocular Therapeutix quarterly revenues are $17.1M, which are larger than Ocugen quarterly revenues of $764K. Ocular Therapeutix's net income of -$48.4M is lower than Ocugen's net income of -$13.9M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 19.15x versus 48.06x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of -283.27% compared to Ocular Therapeutix's net margin of 21.57%. Ocular Therapeutix's return on equity of -62.66% beat TG Therapeutics's return on equity of 12.81%.

Ocular Therapeutix has a consensus price target of $17.50, signalling upside risk potential of 126.98%. On the other hand TG Therapeutics has an analysts' consensus of $43.00 which suggests that it could grow by 4.04%. Given that Ocular Therapeutix has higher upside potential than TG Therapeutics, analysts believe Ocular Therapeutix is more attractive than TG Therapeutics.

Ocular Therapeutix has a beta of 1.491, which suggesting that the stock is 49.133% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.139, suggesting its more volatile than the S&P 500 by 113.867%.

Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Ocular Therapeutix quarterly revenues are $17.1M, which are smaller than TG Therapeutics quarterly revenues of $108.2M. Ocular Therapeutix's net income of -$48.4M is lower than TG Therapeutics's net income of $23.3M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 295.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 19.15x versus 19.68x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Xeris Biopharma Holdings has a net margin of -283.27% compared to Ocular Therapeutix's net margin of -8.51%. Ocular Therapeutix's return on equity of -62.66% beat Xeris Biopharma Holdings's return on equity of -1019.2%.

Ocular Therapeutix has a consensus price target of $17.50, signalling upside risk potential of 126.98%. On the other hand Xeris Biopharma Holdings has an analysts' consensus of $6.08 which suggests that it could grow by 45.01%. Given that Ocular Therapeutix has higher upside potential than Xeris Biopharma Holdings, analysts believe Ocular Therapeutix is more attractive than Xeris Biopharma Holdings.

Ocular Therapeutix has a beta of 1.491, which suggesting that the stock is 49.133% more volatile than S&P 500. In comparison Xeris Biopharma Holdings has a beta of 1.094, suggesting its more volatile than the S&P 500 by 9.436%.

Ocular Therapeutix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xeris Biopharma Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ocular Therapeutix pays -- of its earnings as a dividend. Xeris Biopharma Holdings pays out -- of its earnings as a dividend.

Ocular Therapeutix quarterly revenues are $17.1M, which are smaller than Xeris Biopharma Holdings quarterly revenues of $60.1M. Ocular Therapeutix's net income of -$48.4M is lower than Xeris Biopharma Holdings's net income of -$5.1M. Notably, Ocular Therapeutix's price-to-earnings ratio is -- while Xeris Biopharma Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ocular Therapeutix is 19.15x versus 3.12x for Xeris Biopharma Holdings. Usually stocks with elevated PS ratios are considered overvalued.